16.55
price down icon0.66%   -0.11
after-market Handel nachbörslich: 16.37 -0.18 -1.09%
loading
Schlusskurs vom Vortag:
$16.66
Offen:
$16.87
24-Stunden-Volumen:
21,569
Relative Volume:
0.54
Marktkapitalisierung:
$317.95M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-20.95
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
-3.95%
1M Leistung:
-6.76%
6M Leistung:
+79.42%
1J Leistung:
-26.12%
1-Tages-Spanne:
Value
$15.94
$17.31
1-Wochen-Bereich:
Value
$15.94
$17.59
52-Wochen-Spanne:
Value
$7.65
$30.00

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Firmenname
Lyell Immunopharma Inc
Name
Telefon
650 695-0677
Name
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Mitarbeiter
300
Name
Twitter
Name
Nächster Verdiensttermin
2025-03-12
Name
Neueste SEC-Einreichungen
Name
LYEL's Discussions on Twitter

Vergleichen Sie LYEL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LYEL
Lyell Immunopharma Inc
16.55 320.06M 54,000 -210.26M -159.01M -0.79
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.00 109.11B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
642.25 68.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
434.07 60.25B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
826.28 50.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
186.23 40.44B 447.02M -1.18B -868.57M -6.1812

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-10-30 Herabstufung BofA Securities Buy → Underperform
2024-06-27 Herabstufung H.C. Wainwright Buy → Neutral
2023-08-28 Herabstufung JP Morgan Overweight → Neutral
2022-11-14 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-11-11 Herabstufung Goldman Buy → Neutral
2022-10-17 Eingeleitet H.C. Wainwright Buy
2021-07-12 Eingeleitet BofA Securities Buy
2021-07-12 Eingeleitet Goldman Buy
2021-07-12 Eingeleitet JP Morgan Overweight
2021-07-12 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten

pulisher
Nov 03, 2025

Strategies to average down on Lyell Immunopharma Inc.2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Lyell’s dual-targeting CAR T-cell therapy shows promise in lymphoma - Investing.com Nigeria

Nov 03, 2025
pulisher
Nov 03, 2025

Is Lyell Immunopharma Inc. stock overvalued by current metricsTrade Analysis Report & Expert Verified Stock Movement Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

How Lyell Immunopharma Inc. stock performs in weak economyWeekly Profit Recap & Daily Volume Surge Signals - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Lyell Immunopharma Appoints New Financial Leadership Team - TipRanks

Nov 03, 2025
pulisher
Nov 03, 2025

Lyell (Nasdaq: LYEL) to present Phase 1/2 ronde-cel LBCL at ASH; FDA RMAT & Fast Track - Stock Titan

Nov 03, 2025
pulisher
Nov 03, 2025

Lyell Immunopharma Announces Key Management Appointments - TradingView

Nov 03, 2025
pulisher
Nov 03, 2025

[8-K] Lyell Immunopharma, Inc. Reports Material Event | LYEL SEC FilingForm 8-K - Stock Titan

Nov 03, 2025
pulisher
Nov 03, 2025

Will Lyell Immunopharma Inc. benefit from macro trendsCPI Data & Low Volatility Stock Recommendations - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is Lyell Immunopharma Inc. stock attractive for retirement portfoliosQuarterly Portfolio Review & Expert Curated Trade Setup Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Volatility clustering patterns for Lyell Immunopharma Inc.July 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Real time social sentiment graph for Lyell Immunopharma Inc.2025 Momentum Check & Stock Portfolio Risk Management - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

How institutional ownership impacts Lyell Immunopharma Inc. stockFed Meeting & Comprehensive Market Scan Reports - newser.com

Nov 03, 2025
pulisher
Nov 02, 2025

What hedge fund activity signals for Lyell Immunopharma Inc. stockProfit Target & Risk Controlled Swing Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Is this a good reentry point in Lyell Immunopharma Inc.Trade Risk Report & Low Drawdown Trading Techniques - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Tick level data insight on Lyell Immunopharma Inc. volatilityTrade Analysis Summary & Safe Capital Allocation Plans - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

How to manage a losing position in Lyell Immunopharma Inc.July 2025 EndofMonth & Free Low Drawdown Momentum Trade Ideas - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

How to track smart money flows in Lyell Immunopharma Inc.July 2025 Update & Trade Opportunity Analysis - newser.com

Nov 02, 2025
pulisher
Nov 01, 2025

Technical signs of recovery in Lyell Immunopharma Inc.2025 Buyback Activity & Weekly Chart Analysis and Guides - newser.com

Nov 01, 2025
pulisher
Oct 31, 2025

Published on: 2025-10-31 03:26:35 - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

Is it too late to sell Lyell Immunopharma Inc.Portfolio Gains Report & Weekly Stock Performance Updates - newser.com

Oct 31, 2025
pulisher
Oct 31, 2025

Is Lyell Immunopharma Inc. still worth holding after the dipWeekly Profit Recap & Precise Swing Trade Entry Alerts - newser.com

Oct 31, 2025
pulisher
Oct 30, 2025

Published on: 2025-10-30 06:17:45 - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Thursday - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Published on: 2025-10-30 02:39:25 - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

[Form 4] Lyell Immunopharma, Inc. Insider Trading Activity - Stock Titan

Oct 29, 2025
pulisher
Oct 28, 2025

Published on: 2025-10-28 05:46:43 - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Lyell Immunopharma Inc Stock Analysis and ForecastTrading Psychology Tips & Achieve Triple Digit Returns - earlytimes.in

Oct 28, 2025

Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$37.30
price down icon 0.64%
$28.71
price up icon 0.35%
$101.57
price up icon 8.65%
$103.95
price up icon 0.04%
biotechnology ONC
$311.86
price up icon 0.44%
$186.23
price down icon 1.78%
Kapitalisierung:     |  Volumen (24h):